Biontech and cepi announce partnership to advance mrna mpox vaccine development and support cepi's 100 days mission

Mainz, germany, and oslo, norway, september 18, 2023 — biontech se (nasdaq: bntx, “biontech”, "the company") and the  coalition for epidemic preparedness innovations  (cepi) today announced a strategic partnership to advance mrna-based vaccine candidates with the development of bnt166 for the prevention of mpox (formerly monkeypox, caused by a member of the orthopoxvirus viral family), an infectious disease that can lead to severe, life-threatening complications. mpox gained global attention in may 2022 with an increasing number of cases that then developed into an international outbreak.1,2 cepi will provide funding of up to $90 million to support the development of mrna-based vaccine candidates.
BNTX Ratings Summary
BNTX Quant Ranking